바이오시밀러 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Biosimilars Market size is expected to reach USD 152.97 Billion in 2034 from USD 39.73 Billion (2025) growing at a CAGR of 16.16% during 2026-2034.

The biosimilars market is entering a critical growth phase as patent expirations of biologics and regulatory support for cost-effective alternatives expand. Future biosimilar development will leverage advanced cell line engineering, process optimization, and AI-driven predictive modeling to ensure consistent quality, efficacy, and safety. Integration with pharmacovigilance platforms and real-time batch analytics will accelerate regulatory approval and market readiness.

Emerging bioprocessing innovations, including continuous manufacturing, high-yield upstream processing, and precision purification technologies, will reduce production costs and improve scalability. AI-assisted clinical trial design and patient stratification will enhance efficacy evaluation while shortening development timelines. Integration with digital health platforms will enable real-time monitoring of treatment outcomes and adverse events.

Future market growth will be driven by healthcare cost containment, global biologics demand, and adoption of precision medicine strategies. By combining process innovation, regulatory intelligence, and digital monitoring, biosimilars will expand access to life-saving biologics, enhancing affordability and treatment efficacy worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins

By Application

• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Rheumatoid Arthritis
• Chronic and Autoimmune Disorders
• Others

COMPANIES PROFILED

• Amgen Inc, F HoffmanLa Roche Ltd, Sandoz International GmbH, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Biopis, Biocon, Viatris Inc, Celltrion Healthcare Co Ltd, AbbVie Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMILARS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Recombinant Non-glycosylated Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Recombinant Glycosylated Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMILARS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Blood Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Growth Hormonal Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Chronic and Autoimmune Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMILARS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BIOSIMILARS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Amgen Inc
  • 8.2.2 F Hoffman-La Roche Ltd
  • 8.2.3 Sandoz International GmbH
  • 8.2.4 Dr. Reddy'S Laboratories Ltd
  • 8.2.5 Teva Pharmaceutical Industries Ltd
  • 8.2.6 Pfizer Inc
  • 8.2.7 Samsung Biopis
  • 8.2.8 Biocon
  • 8.2.9 Viatris Inc
  • 8.2.10 Celltrion Healthcare Co. Ltd
  • 8.2.11 AbbVie Inc